About Inflabloc Pharmaceuticals
Inflabloc Pharmaceuticals, Inc. is engaged in the research and development of pharmaceutical treatments for inflammatory disorders. Inflabloc's current product development is based on its discoveries of strong anti-inflammatory properties of dehydroepiandrosterone (DHEA), a steroid that is produced in the adrenal gland. The company's lead product line is a DHEA combination treatment. The company has 4 products in development. IP-1001 is slated to enter Phase 2 clinical trials in Crohn's disease later this year. IP-1002 has completed Phase 1. IP-1003 recently established proof-of-concept in an inflammatory bowel disease (IBD) animal model, while IP-1005 has just entered proof-of-concept testing in a C-reactive protein (CRP) mouse model.
Missing: Inflabloc Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Inflabloc Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Inflabloc Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Inflabloc Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Inflabloc Pharmaceuticals Frequently Asked Questions (FAQ)
When was Inflabloc Pharmaceuticals founded?
Inflabloc Pharmaceuticals was founded in 1991.
Where is Inflabloc Pharmaceuticals's headquarters?
Inflabloc Pharmaceuticals's headquarters is located at 2150 West Dauntless Avenue, Salt Lake City.
What is Inflabloc Pharmaceuticals's latest funding round?
Inflabloc Pharmaceuticals's latest funding round is Series C.
How much did Inflabloc Pharmaceuticals raise?
Inflabloc Pharmaceuticals raised a total of $46.1M.
Who are the investors of Inflabloc Pharmaceuticals?
Investors of Inflabloc Pharmaceuticals include Friedli Corporate Finance, vSpring Capital, Two Rivers Angel Investment Network, New Venturetec, Technology Funding and 5 more.
Who are Inflabloc Pharmaceuticals's competitors?
Competitors of Inflabloc Pharmaceuticals include Humanetics, Aquinox Pharmaceuticals, Intas Pharmaceuticals, Esperance Pharmaceuticals, Xhale, Altheus Therapeutics, RetroScreen Virology, Wilmington Pharmaceuticals, Amira Pharmaceuticals, Resolvyx Pharmaceuticals and 20 more.
Compare Inflabloc Pharmaceuticals to Competitors
Morria's lead products are first-in-class synthetic anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAID). These drugs target a known but previously elusive key event in the inflammation process upstream of current competitors while simultaneously protecting cells and tissues against inflammatory damage and stimuli. Morria has two lead products (MRX4 for allergic rhinitis and MRX6 for contact dermatitis) scheduled for clinical trials in late 2007 and a growing library of additional compounds. Double blind placebo controlled human pilot-studies for contact dermatitis have been successfully completed in Israel .nMorria is also currently engaged in research agreements with three global pharmaceutical leaders in the fields of ophthalmology, eye-care and cardiovascular medicine.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Choice Research of Birmingham is a company that manages clinical development trials.
Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.
Charleston Laboratories, Inc is a specialty pharmaceutical company focused on the research and development of pain products that prevent or significantly reduce nausea and vomiting, the two most burdensome side effects related to opioid analgesics and other pain associated disease states.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.